Clemastine Fumarate
규격
14976-57-9CAS 번호
239-055-2EC 번호
(E)-but-2-enedioic acid;(2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidineIUPAC 명칭
C25H30ClNO5화학식
460 g/mol분자량
CLEMASTINE FUMARATE; 14976-57-9; Agasten; Tavist; Mecloprodine; Aloginan; Xolamin; Clemastine hydrogen fumarate; Alphamin; Anhistan; Clemanil; Fuluminol; Inbestan; Kinotomin; Lacretin; Marsthine; Masletine; Lecasol; Piloral; Reconin; Tavegil; Trabest; Mallermin-F; Telgin-G; Tavist-1; Meclastine hydrogen fumarate; DTXSID6047785; 19259EGQ3D; CHEBI:3739; (+)-(2R)-2-(2-(((R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine fumarate (1:1); DTXCID6027765; (+)-2-(2-((p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methyl pyrrolidine fumarate; RefChem:56360; (2R)-2-(2-((1R)-1-(4-Chlorophenyl)-1-phenylethoxy)ethyl)-1-methylpyrrolidine monofumarate; (R)-2-(2-((R)-1-(4-chlorophenyl)-1-phenylethoxy)ethyl)-1-methylpyrrolidine fumarate; Clemastine (fumarate); MFCD00137486; C25H30ClNO5; Pyrrolidine,2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methyl-, (2R)-,(2E)-2-butenedioate (1:1); Maikohis; Tavegyl; Pyrrolidine, 2-(2-(1-(4-chlorophenyl)-1-phenylethoxy)ethyl)-1-methyl-, (R-(R*,R*))-, (E)-2-butenedioate (1:1); Pyrrolidine, 2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methyl-, (2R)-, (2E)-2-butenedioate (1:1); HS-592;Meclastine; Meclastine fumarate; HSDB 6507; Topcare dayhist allergy; NCGC00016710-01; Contac 12 Hour Allergy; EINECS 239-055-2; CAS-14976-57-9; UNII-19259EGQ3D; (R)-2-[2-[(R)-1-(4-Chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine fumarate; Prestwick_680; HS-592 (fumarate);Meclastine (fumarate); 14976-57-9 (FUMARATE); Clemastine fumarate CRS; Clemastine fumarate [USAN:USP:BAN:JAN]; SCHEMBL33403; SPECTRUM1500191; HY-B0298AR; orb1226182; CHEMBL1200795; HMS500O07; HY-B0298A; CLEMASTINE FUMARATE [JAN]; Clemastine (fumarate) (Standard); CLEMASTINE FUMARATE [HSDB]; CLEMASTINE FUMARATE [USAN]; HMS1568N14; HMS1920O13; HMS2091E20; HMS2095N14; HMS3267L12; HMS3412B19; HMS3676B19; HMS3712N14; HMS3884K12; Pharmakon1600-01500191; CLEMASTINE FUMARATE [VANDF]; (E)-but-2-enedioic acid;(2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine; CLEMASTINE FUMARATE [MART.]; MSK10900; Tox21_110574; CCG-40028; CLEMASTINE FUMARATE [USP-RS]; CLEMASTINE FUMARATE [WHO-DD]; NSC756685; Clemastine for system suitability CRS; AKOS015896237; AKOS037643271; Tox21_110574_1; AC-1338; Clemastine fumarate - Bio-X trade mark; CLEMASTINE FUMARATE [ORANGE BOOK]; CLEMASTINE HYDROGEN FUMARATE [MI]; NCGC00016710-05; NCGC00180903-01; NCGC00180903-02; (R-(R*,R*))-2-(2-(1-(p-Chlorophenyl)-1-phenylethoxy)ethyl)-1-methylpyrrolidinium hydrogen fumarate; AS-12093; BC164321; CLEMASTINE FUMARATE [EP MONOGRAPH]; Pyrrolidine, 2-(2-((p-chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methyl-, (+)-, fumarate (1:1); CLEMASTINE FUMARATE [USP MONOGRAPH]; Clemastine fumarate salt, >=98% (HPLC); SW196835-3; TAVIST-D COMPONENT CLEMASTINE FUMARATE; H10994; C446176; F859378; SR-05000001590; SR-05000001590-1; Q27106180; Clemastine fumarate, European Pharmacopoeia (EP) Reference Standard; Clemastine fumarate, United States Pharmacopeia (USP) Reference Standard; Clemastine for system suitability, European Pharmacopoeia (EP) Reference Standard; (+)-(2R)-2-(2-(((R)-P-CHLORO-.ALPHA.-METHYL-.ALPHA.-PHENYLBENZYL)OXY)ETHYL)-1-METHYLPYRROLIDINE FUMARATE (1:1); (2E)-But-2-enedioic acid--(2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine (1/1); (2E)-but-2-enedioic acid; (2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenyl-ethoxy]ethyl]-1-methyl-pyrrolidine;fumaric acid; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidin-1-ium;(E)-4-hydroxy-4-oxobut-2-enoate; (2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine (2E)-but-2-enedioate; (2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidinium (2E)-3-carboxyprop-2-enoate동의어